PMID- 23845179
OWN - NLM
STAT- MEDLINE
DCOM- 20140714
LR  - 20131007
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 42
IP  - 8
DP  - 2013
TI  - IL4 and IFNalpha generation of dendritic cells reveals great migratory potential 
      and NFkB and cJun expression in IL4DCs.
PG  - 711-25
LID - 10.3109/08820139.2013.809580 [doi]
AB  - Dendritic cells (DCs) recently revealed as a potent tumor vaccine component, are 
      commonly differentiated from monocytes by cultivation with IL-4 and GM-CSF. 
      Despite the different opinions, the use of IFNalpha can promote DCs 
      differentiation and activation. The aim of this study was to compare the 
      functionality and phenotypic characterization of monocyte-derived DC generated by 
      IL-4 (IL4DC) and IFNalpha (IFNalphaDC) modified protocols. To this aim, we 
      investigated the expression of maturation markers, co-stimulatory molecules, 
      relevant miRNA, cytokine and migratory profiles and the functional ability of 
      these cells to stimulate autologous T cells in vitro. We herein investigated the 
      molecular mechanism underlying the parameters previously described, as the 
      relative expression of NF-kB p65, c-fos and c-jun, transcription factors. Our 
      results demonstrated that IL4DC presented a stable phenotype, an increase in 
      migratory capacity and NF-KB activation, in addition to lower levels of miR-146 a 
      and miR-221. We believe that the IL4DC migratory potential and increase in 
      NFkBp65 expression may be involved in higher IL12 expression and migration, 
      suggesting a preferential activation of TH1 immune responses by IL4DC.
FAU - de Azevedo, Maria Teresa Almeida
AU  - de Azevedo MT
AD  - Hemocentro, University of Campinas , Campinas, SP , Brazil.
FAU - Saad, Sara Teresinha Olalla
AU  - Saad ST
FAU - Gilli, Simone Cristina Olenscki
AU  - Gilli SC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130711
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Interferon-alpha)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - 187348-17-0 (Interleukin-12)
RN  - 207137-56-2 (Interleukin-4)
RN  - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Antigens, Differentiation/metabolism
MH  - *Cancer Vaccines
MH  - Cell Differentiation
MH  - Cell Lineage
MH  - Cell Movement
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunophenotyping
MH  - Interferon-alpha/*immunology
MH  - Interleukin-12/genetics/metabolism
MH  - Interleukin-4/*immunology
MH  - JNK Mitogen-Activated Protein Kinases/metabolism
MH  - Lymphocyte Activation
MH  - MicroRNAs/metabolism
MH  - NF-kappa B/metabolism
MH  - Th1 Cells/*immunology
MH  - Th1-Th2 Balance
EDAT- 2013/07/13 06:00
MHDA- 2014/07/16 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
AID - 10.3109/08820139.2013.809580 [doi]
PST - ppublish
SO  - Immunol Invest. 2013;42(8):711-25. doi: 10.3109/08820139.2013.809580. Epub 2013 
      Jul 11.